Clinical trial · Interventional
Transcatheter Intra-arterial Limb Infusion of Cisplatin for Extremity Osteosarcoma
A Retrospective Study of Extremity Osteosarcoma Patients Who Recieved Intra-arterial Limb Infusion of Cisplatin During Neoadjuvant Chemotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Although there seems to be no benefit from improving the histologic response rate or long-term survival of intra-arterial infusion of cisplatin for localized osteosarcoma of extremities with IOR/OS-3, IOR/OS-5, and COSS 86 protocols, such a treatment strategy is still believed to potentially increase the tumoricidal effect with an increase in higher local concentrations of the infused agents combined with longer tissue exposure time. Besides, the relationship of chemotherapy-induced necrosis and surgical margins is still the main concern for localized osteosarcoma patients to achieve long-term survival. The investigators intend to analyze the gain and loss from transcatheter intra-arterial limb infusion of cisplatin for extremity osteosarcoma in the past six years.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Event-free Survival | — | UNRESOLVED | — |
| Local-recurrence Free Survival | — | UNRESOLVED | — |
| Overall Survival | — | UNRESOLVED | — |
| Pathological Response | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cisplatin | Drug | Cisplatin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- IA group
- description
- Cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion.
- interventionNames
- Drug: Cisplatin
- type
- SHAM_COMPARATOR
- label
- IV group
- description
- Cisplatin was given at 100-120 mg/m2 as 6-h infusions.
- interventionNames
- Drug: Cisplatin
Primary outcomes (2)
- measure
- event-free survival, EFS
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * histological diagnosis of high-grade osteosarcoma * located at extremities * following the PKUPH-OS protocol * accept to recieve IA or IV infusion of cisplatin Exclusion Criteria: * lost to follow-up * did not recieve definitve surgery in Musculoskeletal Tumor Center of Peking University People's Hospital * quiting to recieve chemotherapy
References
Publications (1)
- RESULTXie L, Xu J, Dong S, Gao J, Tang X, Yan T, Yang R, Guo W. Gain and loss from transcatheter intra-arterial limb infusion of cisplatin for extremity osteosarcoma: a retrospective study of 99 cases in the past six years. Cancer Manag Res. 2019 Jul 30;11:7183-7195. doi: 10.2147/CMAR.S214604. eCollection 2019. PMID 31447583